Ada Yonath

Ada Yonath (born 1939) is the Israeli crystallographer who solved the atomic structure of the ribosome, the molecular machine inside every living cell that reads genetic code and builds proteins, after most of the field had concluded the job was impossible. Her 2009 Nobel Prize in Chemistry, shared with Thomas Steitz and Venkatraman Ramakrishnan, made her the first woman to win that prize in 45 years and the first Israeli woman to win a Nobel Prize in any field. The structures her lab produced did not just answer a textbook question. They showed, atom by atom, exactly where more than twenty families of antibiotics dock onto bacterial ribosomes and how bacteria mutate to shrug them off, work now used to design new drugs against resistant infection.

Who she was

Yonath was born in 1939 in the Geula quarter of Jerusalem to a poor family; her father ran a struggling grocery and the family shared cramped housing with other tenants. He died when she was eleven, and the family moved to Tel Aviv, where Yonath cleaned houses, babysat and tutored younger students to help support her mother while keeping her grades up. Her parents had scraped together tuition to send her to a better school in Jerusalem’s Beit HaKerem neighborhood before that, a bet on education that paid off: she returned to Jerusalem for university, earning a bachelor’s degree in chemistry from Hebrew University in 1962 and a master’s in biochemistry in 1964, then a doctorate in X-ray crystallography from the Weizmann Institute in 1968, followed by postdoctoral work at MIT and Carnegie Mellon.

What she set out to solve

The ribosome is the cell’s protein factory: a massive, asymmetric complex of RNA and protein that translates genetic instructions into every protein an organism makes. By the 1970s, several major labs, at UCLA, MIT and Britain’s Medical Research Council, had already tried and failed to determine its structure by X-ray crystallography, the standard technique for mapping molecules atom by atom. The ribosome was considered too large, too flexible and too structurally irregular to ever form the ordered crystals the method requires. When Yonath, newly returned to the Weizmann Institute in 1970 to build Israel’s first biological crystallography lab, proposed to try anyway, colleagues told her it was a dead end and that she would be dead before she got there.

How she got there

Yonath’s team made roughly 25,000 attempts before producing the first usable ribosome crystals worldwide in the early 1980s. Getting crystals to survive long enough under X-ray bombardment to yield data required a method she developed herself, cryo-bio-crystallography: flash-freezing the crystals to about minus 185 degrees Celsius to halt the radiation damage that had wrecked every earlier attempt. She also pulled ribosomes from bacteria adapted to extreme environments, the Dead Sea and hot springs, because their molecular stability held up better under the crystallization process than ribosomes from ordinary bacteria. The approach produced a low-resolution map of a ribosomal subunit by the late 1980s, still contested by skeptics, and then, as two other labs entered the race in the 1990s with their own methods, a genuine three-way competition to reach full atomic resolution. Yonath’s group resolved a complete ribosomal subunit structure in 1999 and full bacterial ribosome structures by 2000 and 2001, work Science magazine named among that year’s ten most important scientific breakthroughs.

What the world got

The atomic-resolution ribosome let Yonath’s team crystallize the structure bound to five different antibiotic compounds, showing precisely which pocket each drug occupies and how it jams the protein-manufacturing process in bacteria without harming the human version. That structural map now underlies the mechanism of more than twenty antibiotic families and explains, at the molecular level, how resistant bacteria mutate the ribosome to dodge them, the basic science behind the ongoing push to design new antibiotics as older ones lose effectiveness against drug-resistant “superbug” infections worldwide. Before Yonath’s work, drug designers were working half-blind; after it, they had a target they could see.

Why this came out of Israel

Yonath spent almost a decade as the only biological crystallographer in the entire country, working with limited equipment on a problem the world’s best-funded labs had abandoned, at an institute built by a state a fraction the size of the countries whose teams she eventually out-raced. That combination, thin resources, real security burdens, and a research culture that treats “impossible” as a starting point rather than a stop sign, is the same pattern behind Israel’s outsized run of scientific and technological breakthroughs, from Dan Shechtman’s quasicrystals to the country’s drip-irrigation and medical-device inventors. Israelis have a word for the stubbornness it takes: chutzpah, the nerve to keep going after everyone credentialed has told you to stop.

The strongest objection, and why it fails

Critics note that Yonath’s early, lower-resolution ribosome models were contested within structural biology, and that the 2009 Nobel Prize was split three ways rather than awarded to her alone, evidence, the argument runs, that the breakthrough belongs to the field collectively rather than to any one scientist. The record does not support discounting her role. Once Steitz’s and Ramakrishnan’s labs entered the field, three groups were racing toward full atomic resolution at once, publishing overlapping high-resolution structures within about two years of each other, but that race existed only because Yonath had already proven, through 25,000 failures and years of open scientific mockery, that crystallizing the ribosome was possible at all. The Nobel committee’s three-way split reflects how contested and collective the final push actually was, not a discount on the discovery that opened the door to it.